ES2034790T3 - Empleo de al menos una citroquina para la preparacion de un medicamento para el tratamiento sistematico de lesiones preneoplasticas. - Google Patents

Empleo de al menos una citroquina para la preparacion de un medicamento para el tratamiento sistematico de lesiones preneoplasticas.

Info

Publication number
ES2034790T3
ES2034790T3 ES199090106221T ES90106221T ES2034790T3 ES 2034790 T3 ES2034790 T3 ES 2034790T3 ES 199090106221 T ES199090106221 T ES 199090106221T ES 90106221 T ES90106221 T ES 90106221T ES 2034790 T3 ES2034790 T3 ES 2034790T3
Authority
ES
Spain
Prior art keywords
preneoplastic
citroquine
injuries
preparation
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES199090106221T
Other languages
English (en)
Spanish (es)
Inventor
Jacques Prof. Boniver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2034790T3 publication Critical patent/ES2034790T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
ES199090106221T 1989-04-11 1990-03-31 Empleo de al menos una citroquina para la preparacion de un medicamento para el tratamiento sistematico de lesiones preneoplasticas. Expired - Lifetime ES2034790T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3911720 1989-04-11
DE4005416 1990-02-21

Publications (1)

Publication Number Publication Date
ES2034790T3 true ES2034790T3 (es) 1993-04-01

Family

ID=25879777

Family Applications (1)

Application Number Title Priority Date Filing Date
ES199090106221T Expired - Lifetime ES2034790T3 (es) 1989-04-11 1990-03-31 Empleo de al menos una citroquina para la preparacion de un medicamento para el tratamiento sistematico de lesiones preneoplasticas.

Country Status (14)

Country Link
US (1) US5128126A (enExample)
EP (1) EP0392300B1 (enExample)
JP (1) JPH02304027A (enExample)
KR (1) KR900015754A (enExample)
AT (1) ATE79763T1 (enExample)
AU (1) AU638982B2 (enExample)
CA (1) CA2014130A1 (enExample)
DE (1) DE59000270D1 (enExample)
DK (1) DK0392300T3 (enExample)
ES (1) ES2034790T3 (enExample)
GR (1) GR3005528T3 (enExample)
HU (1) HU206834B (enExample)
IE (1) IE64765B1 (enExample)
IL (1) IL94052A (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
WO1993011769A1 (fr) * 1991-12-10 1993-06-24 Otsuka Pharmaceutical Co., Ltd Agent anticancereux
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
WO1999040929A1 (en) * 1998-02-12 1999-08-19 The General Hospital Corporation Methods to potentiate cancer therapies
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
EP1276856A4 (en) * 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
US20050118137A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20050201981A1 (en) * 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US20040247565A1 (en) * 2000-07-19 2004-12-09 Chih-Ping Liu Method of treatment using interferon-tau
US20050118138A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
WO2002022848A2 (en) * 2000-09-12 2002-03-21 Genetrol Biotherapeutics, Inc. Compositions comprising mixtures of human cytokines and methods of producing the same
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
JP2004532213A (ja) * 2001-04-06 2004-10-21 ザ ユニヴァーシティ オヴ シカゴ Ｅｇｒ−１プロモーター活性の化学療法誘導
EP1401477A4 (en) * 2001-05-25 2005-02-02 Human Genome Sciences CHIMIOKINE BETA-1 HYBRID PROTEINS
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
WO2005065079A2 (en) * 2003-11-10 2005-07-21 Angiotech International Ag Medical implants and fibrosis-inducing agents
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
WO2006026348A1 (en) * 2004-08-25 2006-03-09 The University Of Chicago Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
EP1977759A1 (en) * 2007-03-27 2008-10-08 4Sc Ag Pharmaceutical composition comprising a cytokine
US20080241100A1 (en) * 2007-03-27 2008-10-02 Stefan Strobl Pharmaceutical composition comprising a cytokine
WO2008116919A1 (en) * 2007-03-27 2008-10-02 4Sc Ag Pharmaceutical composition comprising a cytokine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9051882A (en) * 1981-10-08 1983-04-27 Berg, Kurt Frimann Method and composition for treating a patient suffering from interferon-susceptible disorders
WO1983001198A1 (en) * 1981-10-08 1983-04-14 Kurt Frimann Berg Method and composition for treating a patient suffering from interferon-susceptible disorder
US4507281A (en) * 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
DE3278234D1 (en) * 1981-10-13 1988-04-21 Exovir Inc Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like

Also Published As

Publication number Publication date
ATE79763T1 (de) 1992-09-15
KR900015754A (ko) 1990-11-10
EP0392300A1 (de) 1990-10-17
GR3005528T3 (enExample) 1993-06-07
HUT54303A (en) 1991-02-28
US5128126A (en) 1992-07-07
CA2014130A1 (en) 1990-10-11
DE59000270D1 (de) 1992-10-01
HU206834B (en) 1993-01-28
AU5310590A (en) 1990-10-18
DK0392300T3 (da) 1992-09-28
HU902145D0 (en) 1990-07-28
AU638982B2 (en) 1993-07-15
IE64765B1 (en) 1995-09-06
IE901297L (en) 1990-10-11
IL94052A (en) 1995-06-29
JPH02304027A (ja) 1990-12-17
IL94052A0 (en) 1991-01-31
EP0392300B1 (de) 1992-08-26

Similar Documents

Publication Publication Date Title
ES2034790T3 (es) Empleo de al menos una citroquina para la preparacion de un medicamento para el tratamiento sistematico de lesiones preneoplasticas.
ES2080307T3 (es) Composiciones farmaceuticas.
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
NZ228130A (en) Therapeutic composition comprising fenofibrate and a solid surfactant which has been co-micronised; preparatory process
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
PT97476A (pt) Processo de preparacao de composicoes farmaceuticas para distribuicao sub-lingual de medicamentos a base de, entre outros, calcitonina, hormona de crescimento humano ou nifedipina
ATE75945T1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
ES2053429T3 (es) El uso de buspirona para la preparacion de composiciones farmaceuticas para aliviar la ansiedad fobica.
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
EP0230264A3 (en) Pharmaceutical composition for nasal application, process for its preparation and its use
FR2651435B1 (enExample)
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
ES2059130T3 (es) Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado.
DE3771584D1 (de) Zusammensetzungen und anwendung von interleukin-2 und/oder interferon-beta und des tumor-necrosis-faktors fuer eine kombinationstherapie oder zur herstellung von arzneimitteln oder formulierungen.
ATE184195T1 (de) Pharmazeutische zusammensetzung, die ein allgemeines anästhetikum ung selegilin enthält
DE68900926D1 (de) Pharmazeutische zubereitung, die zidovudin und inosiplex oder bestandteile davon enthaelt, fuer die behandlung von aids-verwandten syndromen.
ITRM920535A0 (it) Composizione farmaceutica per la somministrazione attraverso le mucose.
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
EP0384302A3 (en) Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome
ES2059442T3 (es) Uso de gepirona para la preparacion de composiciones farmaceuticas para mitigar alteraciones de panico.
CA2247998A1 (en) Fragments of cr1 and their use
MX9401370A (es) Terapia antiviral.
ITMI922332A1 (it) Composizioni farmaceutiche per la somministrazione di paratormone, suoi frammenti biologicamente attivi o peptidi correlati per via rettale.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 392300

Country of ref document: ES